Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Manmeet S. Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E. Berens, Tobias Walbert, Matthias Holdhoff, Glenn J. Lesser, Timothy F. Cloughesy, Andrew E. Sloan, Naoko Takebe, Marta Couce, David M. Peereboom, Burt Nabors, Patrick Y. Wen, Stuart A. Grossman, Lisa R. RogersClinical 2024 · DOI

Abstract

These findings confirm the safety and feasibility of TRC102+TMZ in patients with rGBM. They also warrant further evaluation of combination therapy in biomarker-enriched trials enrolling GBM patients with baseline hyperactivated DDR pathways.
BibTeX
@inproceedings{ahluwalia2024evaluating,
  author = {Manmeet S. Ahluwalia and Ahmad Ozair and Jan Drappatz and Xiaobu Ye and Sen Peng and Matthew Lee and Sanhita Rath and Harshil Dhruv and Yue Hao and Michael E. Berens and Tobias Walbert and Matthias Holdhoff and Glenn J. Lesser and Timothy F. Cloughesy and Andrew E. Sloan and Naoko Takebe and Marta Couce and David M. Peereboom and Burt Nabors and Patrick Y. Wen and Stuart A. Grossman and Lisa R. Rogers},
  title = {{Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1158/1078-0432.ccr-23-4098},
}

Loading related content...

Figure